With global pepective while rooted in China, InnoCare is a biopharmaceutical company focused on discovery and development of innovative drug for treatment of cancer and autoimmune diseases. Founded by world-renowned structural biologists and world top scientists, InnoCare has a core scientific team with solid education background and rich drug discovery experience in the US and a strong Scientific Advisory Board (SAB) which coists of academic leade from top univeities, famous scientists from pharmaceutical industry and clinical experts from national top hospitals. InnoCare is aggressively forging an important pathway forward in defeating disease and pushing the innovation boundaries into unchartered territories.

InnoCare’s mission is to be a global leading biopharmaceutical company by producing effective and affordable immunotherapy medicines and anticancer products for patients among which Chinese patients are our primary target. The reason we pay special attention to Chinese patients is because we realized the incidence rate of oncology diseases such as liver cancer, gastrointestinal cancer, and autoimmune diseases including lupus and rheumatoid arthritis have been kept high in China and also lack of effective treatments and cures. To reach our goal, we synergize multiple ways including internally research and development, liceing in and international collaboration to develop the Fit-in-Class or Best-in-Class drugs.

InnoCare是一家植根中国且具全球视野的新药创制公司。公司由世界著名的结构生物学家和在国际顶尖制药公司积累数十年经验的新药研究专家共同发起设立，核心研究团队成员都有长期在美国学习和在跨国制药公司担任研发高管的经历。他们与由来自清华、北大的生命科学领域学术带头人、跨国制药公司新药研究专家以及国内顶尖医院的医疗专家组成的科学顾问委员会一起，构成公司核心竞争力的重要组成部分。

面对在中国发病率居高不下且缺乏有效药物治疗的肝癌、胃癌等肿瘤疾病以及类风湿关节炎、系统性红斑狼疮等自身免疫疾病，InnoCare自创立之日起，就把“为国人创制有效治疗肿瘤与自身免疫系统疾病且费用合理的新药” 作为自己的使命。为达成这一使命，我们专注于国际一类新药与新技术产品开发，通过“自主研发、在研药物引进与国际合作”等途径，有效整合各方资源并加快新药研究在中国从实验室到医院的进程，在帮助中国患者尽早用到国际一类新药的同时，把公司打造成国内外生物医药行业的领军企业。